Published in Obesity and Diabetes Week, July 4th, 2005
In early April, Biovail and Depomed submitted a complete response to the approvable letter received in February. The response addressed the finalization of one manufacturing specification.
Glumetza may offer potential advantages such as less frequent dosing and proven effectiveness in combination with other diabetes drugs. Glumetza also offers excellent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week